-
2 months ago | 
eyeonivd.com | Bruce Carlson
Increasingly, using other companies to perform manufacturing work has become common in in vitro diagnostics. That would not have been the case two decades ago. With the amount of tests that are coming, there will need to be even more. That’s the point of our most recent webinar on Contract Manufacturing, check it out here: The webinar can only go into so much detail For more numbers and data, our report is available: CONTRACT MANUFACTURING IN IVD MARKETS – Eye On IVD
-
2 months ago | 
eyeonivd.com | Bruce Carlson
The announcement that Franklin Lakes, NJ-based Becton Dickinson is going to spin off its diagnostics (and life sci) unit and concentrate on medical technology made news this week. While we didn’t prognosticate it, it’s not surprising. Becton Dickinson (BD) is into a lot. It’s huge in specimen handling, both in volume and innovation. It’s a leader in microbiology, which let’s face it, could be a whole company in and of itself, given the needs there.
-
2 months ago | 
eyeonivd.com | Bruce Carlson
Sign up now, there’s only 100 slots for this webinar.JOIN HERE FOR ZOOM WEBINAR: https://us06web.zoom.us/webinar/register/WN_RpmYgJtFS_qbg5HZNEZfEg
-
2 months ago | 
eyeonivd.com | Bruce Carlson
OK, we are paraphrasing here. But if you look at the recent approvals, you see in vitro diagnostic test makers saying it, adopting an approach of let’s test for what can best help providers. Don’t get their intentions wrong, they plan to sell the big comprehensive tests too. But what they are pushing is testing for the important.
-
Jan 22, 2025 | 
eyeonivd.com | Bruce Carlson
The 2025 J.P. Morgan Healthcare Conference wrapped up, and while big pharma M&A received most of the attention this year, there was some under-the-surface news of note for the IVD industry. Here are a few nuggets:Ozempic-Associated Proteomics Test? The trend of increased usage of semaglutide (Ozempic/Wegovy) cannot be ignored by any part of healthcare.
-
Jan 17, 2025 | 
eyeonivd.com | Bruce Carlson
Developments in artificial intelligence and in vitro diagnostics including: regulations, new products, and expert viewpoints are constant. Here we list some notable links in AI and IVD we are tracking. TEMPUS AI WILL BUY AMBRY: Tempus AI has announced an agreement to acquire Ambry Genetics for $375 million in cash and $225 million in shares. Ambry is Tempus’ primary reference lab. The deal will combine Ambry’s extensive genetic testing capabilities with its AI-driven data analytics platform.
-
Jan 15, 2025 | 
eyeonivd.com | Bruce Carlson
It would be a stretch to say the J.P. Morgan Healthcare Conference is an in vitro diagnostics meeting. Healthcare IT and pharmaceutical deals traditionally dominate the handshakes there, and that’s no exception this year. Heck, one pharma deal announced at JPM would equal a seventh of the entire IVD market, just one deal. But we aren’t bitter. In fact, IVD is always represented at JPM, and investors have always been interested; particularly in companion packages and novel tech.
-
Dec 30, 2024 | 
eyeonivd.com | Bruce Carlson
Lab-developed tests, lab consolidation and infectious disease threats dominated the news relative to in vitro diagnostic (IVD) companies in 2024, Eye On IVD notes. Other stories, such as rising fungal infections and studies have not been as but are just as important. These stories have been covered by our Linked In newsletter and our email (subscribe at eye on IVD.com).
-
Dec 17, 2024 | 
eyeonivd.com | Bruce Carlson
You are not likely to get a burkholderia pseudomallei infection. It is, after all, not spread from animals, it’s spread from the soil. It is spread from cut on skin that is exposed to dirt, or in rare cases, from exposure to soil that has entered the airstream, say in an extreme storm. If that sounds terrifying, it should be comforting to know it’s rare.
-
Dec 11, 2024 | 
eyeonivd.com | Bruce Carlson
Among the many predictions made in our latest webinar, “Very Cutting-Edge Trends in IVD” was that we can expect a “lab-in-a-box” type system to receive FDA approval within the next 2 years. We’ll explain why here. But first – we wanted to highlight our EYE ON IVD End of The Year Sale on All of Our Market Research, w/Discounts up to 20%.
